Aspira Women's Health

Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split

Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.

Aspira Women's Health Prices $9M Public Offering

The company is offering 12 million shares of common stock along with warrants to purchase 12 million shares.

Earnings Roundup: DermTech, 908 Devices, OraSure, Codex DNA, Aspira, IsoPlexis, Epigenomics

DermTech, 908 Devices, OraSure Technologies, Codex DNA, Aspira Women's Health, and Epigenomics reported quarterly financial results this week.

Biodesix, Sera Prognostics, Aspira, Epigenomics Post Q1 Financial Results

All four companies posted net losses for the quarter, while Biodesix's results were hit by a sharp decline in COVID-19 testing revenue.

Aspira Q4 Revenues up 36 Percent

The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.

Jan 5, 2022

Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.